A big thank-you to the soft-bashers (and hard basher) who have to resort to ad hominem attacks because they can't refute actual facts. You've shown again that you are awfully worried that we real shareholders will continue buying stock.

When people try to mock someone rather than explaining why they claim that a terrific clinical trial result for a condition with no treatment is "not a huge success" -- well, that tells you something about them and their motives, doesn't it?